Leukemia and Lymphoma

Two posters presented at the European Society of Medical Oncology highlighted the unmet needs of cancer survivors.

A review of current data identified areas of progress in Bruton tyrosine kinase (BTK) inhibition for patients with chronic lymphocytic leukemia (CLL).

This is the third approval for zanubrutinib, which is sold as Brukinsa by BeiGene.

Two posters being presented at the European Society for Medical Oncology Congress 2021 highlighted the need to provide long-term psychosocial support for adolescents who survive childhood leukemia.

In a recent study, researchers were able to show how different evolutionary forces in aging blood stem cells impact whether or not someone develops acute myeloid leukemia (AML), offering insight into those at higher risk of the disease.

Results of a data analysis found once-daily zanubrutinib dosing in patients with mantle cell lymphoma (MCL) is safe and effective.

Unlike most other cancers, the progression of hairy cell leukemia is largely driven by extended cell survival rather than increased proliferative cell fractions.

Ruxolitinib is increasingly being used in patients with graft-vs-host-disease (GVHD); a recent study found a link with transplant-associated thrombotic microangiopathy (TA-TMA) in patients with GVHD treated with the therapy.

The approval of zanubrutinib makes it just the second therapy indicated for this rare type of lymphoma.

The findings, if confirmed in subsequent research, could prove to have significant implications, as only a small subset of patients with chronic lymphocytic leukemia (CLL) respond to chimeric antigen receptor (CAR) T-cell therapy.

The meta-analysis collected findings from 11 studies, from which researchers determined statistical heterogeneity regarding the incidence of GVHD between patients receiving only HSC transplantation or only killer cell therapy, and patients receiving HSC transplantation in addition to killer cell therapy.

A recent study found that older age, male gender, lack of surgical resection or chemotherapy, and late-stage disease may be poor prognostic factors for diffuse large B-cell lymphoma (DLBCL) of the urinary tract.

The researchers of a new analysis argue that the treatments they investigated for acute myelogenous leukemia (AML) are worthy of clinical promotion based on their findings, which they say also provide evidence-based guidance for clinical practice.

Over the course of treatment, patients with relapsed/refractory acute myeloid leukemia (AML) may acquire new TP53 mutations, making ongoing monitoring for mutations crucial.

doi: 10.37765/ajmc.2021.88733

The breast cancer drug palbociclib may be able to treat myelofibrosis either alone or in combination with ruxolitinib.

Chemotherapy is standard care for pediatric acute lymphoblastic leukemia (ALL), but new research shows thiopurines can cause mutations that result in relapse.

Treatment-related modifications have resulted in improved long-term outcomes for all adolescent and young adult (AYA) survivors of Hodgkin lymphoma, but new research highlights that racial, ethnic, and socioeconomic status disparities persist in the long term.

In an interim analyses of the phase 3 SEQUOIA trial, zanubrutinib had superior progression-free survival compared with bendamustine plus rituximab in patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL).

In a recent review article, a researcher outlined current guidance for the management of patients with chronic lymphocytic leukemia (CLL) as the pandemic continues throughout the country.

Across 19 patients, 73% developed grade 3 or 4 neutropenia, significantly higher than the incidence observed in the phase 3 trial examining the combination for chronic lymphocytic leukemia (CLL).

A new treatment using human immune cells can prevent infections in patients with leukemia who have a weakened immune system due to treatment for their disease.

Based on subgroup analyses of over 500 younger patients with intermediate-risk disease, the researchers say measurable residual disease (MRD)-guided decisions may help achieve better outcomes postremission.

Posters presented at the European Hematology Association 2021 Virtual Congress evaluated acute myeloid leukemia (AML) in elderly patients.

The researchers outlined patient selection for treatment, adverse event management, and future strategies for the treatment of these patients.

A retrospective analysis of real-world data found a discrepancy between actual care and the recommendations from clinical trials for patients with mantle cell lymphoma, resulting in outcomes that were worse than in trials.

Two abstracts presented recently at the American Society of Clinical Oncology annual meeting offered promising data for 2 CAR T-cell therapies, one in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and one in R/R multiple myeloma.

The National Comprehensive Cancer Network (NCCN) has updated its guidelines for Waldenström macroglobulinemia to include zanubrutinib (Brukinsa) as a preferred regimen.

An analysis of social media posts provides insight into patient experiences of acute lymphoblastic leukemia (ALL) and the therapies that treat it.